title: Glyn Edwards talks about cancer drug development at Antisoma. Interview by Ulrike Knies-Bamforth and Dan Huke.
abstract: We're an exclusively oncology development-focused company; we've put together a portfolio of projects, which are rather different from each other, which is our way of diversifying the systemic risk out of the portfolio.
authors.affiliation: Antisoma, West Africa House, Hanger Lane, London, W5 3QR, UK.
authors.forename: Glyn
authors.initials: G
authors.lastname: Edwards
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D035843:Biomedical Research; D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000458:organization & administration*; D009369:Neoplasms / Q000188:drug therapy*; D009937:Organizational Objectives
chemical_list: D000970:Antineoplastic Agents